New Silk Route

New Silk Route (NSR) is a leading private equity and growth capital firm founded in 2006, specializing in investments across the Indian subcontinent, the Middle East, and other rapidly growing Asian economies. The firm manages over $1 billion in assets and maintains a significant focus on the healthcare, life sciences, and pharmaceutical sectors. NSR's portfolio has included notable companies such as Nectar Lifesciences, HealthCare Global (HCG), and Alloy Therapeutics, reflecting its strategic interest in healthcare infrastructure, oncology, and drug discovery tools. Led by CEO and Co-Founder Parag Saxena, the firm emphasizes operational excellence and often takes control positions to drive growth and transformation in its portfolio companies. NSR operates from offices in New York, Mumbai, Bengaluru, and Dubai.